A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)

What this Trial Is About

This observational study focuses on patients aged 18 and older who have lymphoproliferative disorders, a group of blood cancers affecting the lymphatic system. Researchers aim to understand the overall survival over 10 years for different types of these disorders. The study also examines factors like patient fitness, comorbid conditions, and how these influence treatment choices and outcomes. New therapies including chemo-free protocols, targeted drugs, and cell therapies are being evaluated to determine the best treatment sequences for cases that are refractory or relapsed. Participants will be observed through various phases of their disease, including diagnosis and treatment stages. The study investigates the impact of clinical and biological factors on disease progression or relapse, as well as potential links between genetic profiles and clinical outcomes. It also monitors adverse events like tumor lysis syndrome and their effects on treatment adjustments. Additionally, the study looks at patients managed with a watch-and-wait approach, long-term toxicities, secondary cancers, and healthcare resource use. Throughout the study, participants' health and treatment outcomes will be regularly assessed using clinical data collected from diagnosis through follow-up. Researchers will analyze survival rates, treatment effectiveness, and side effects over a long period from 2002 to 2030. This comprehensive data collection aims to improve understanding of lymphoproliferative disorders and optimize patient management strategies over time.

A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)